This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Progenics, Wyeth Bowel Drug Fails Phase III Study

Updated from 9:14 a.m. EDT

Progenics (PGNX - Get Report) and Wyeth (WYE) said Wednesday that their experimental bowel drug, intravenous methylnaltrexone, failed a phase III study in patients undergoing surgery.

The negative results are a significant setback for the drug, also known as MNTX, as the companies face competition from another, similar bowel drug being developed by Adolor (ADLR) and GlaxoSmithKline (GSK - Get Report).

Progenics shares closed Tuesday at $13.55. The stock was tumbling 57% to $5.76 in morning trading Wednesday.

The failed phase III study investigated the use of MNTX as a treatment for post-operative ileus, a medical term for painful bloating and constipation following abdominal surgery.

Progenics and Wyeth said MNTX, administered intravenously, did not reduce the time required for gastrointestinal function to return to normal, compared to a placebo. The drug also failed to help patients leave the hospital sooner.

The companies are conducting a second phase III study with a similar design. Results are expected in the middle of the year.

There are no drugs currently approved to treat POI. That, however, may change in May, when the Food and Drug Administration is expected to issue a decision on Entereg, a bowel drug administered as a pill that is being developed by Adolor and GlaxoSmithKline.

In early February, the FDA pushed back the decision date on Entereg to take more time to review the drug's data, including a risk-management plan submitted by the companies to better inform doctors and patients of safety risks.

(Full disclosure, I had been bullish on Progenics since the stock was $18 and bearish on Adolor because I thought MNTX was a superior drug. Clearly, Wednesday's negative study results from MNTX is a big knock to that call.)

MNTX is a variation of naltrexone, a drug approved and used today to treat opioid and alcohol dependence.

MNTX has been filed with the FDA for the treatment of patients with advanced medical illness. These are nursing home and hospice patients in the advanced stages of disease who require heavy doses of painkillers.

An FDA approval decision was expected in February, but was pushed back until April so the agency could review more safety data.

Know What You Own: Progenics operates in the pharmaceutical sector of the healthcare industry, and some of the other stocks in its field include Eli Lilly (LLY - Get Report), Novartis (NVS - Get Report) and Pfizer (PFE - Get Report). These stocks were recently trading at $50.23, $48.07 and $21.46, respectively.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GSK $43.36 -0.25%
LLY $76.23 -0.37%
NVS $76.80 -0.23%
PFE $32.92 -0.23%
PGNX $5.47 0.18%


Chart of I:DJI
DOW 17,820.48 -221.07 -1.23%
S&P 500 2,075.31 -19.84 -0.95%
NASDAQ 4,808.5970 -54.5440 -1.12%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs